Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ok, thanks.
Hi JTFM, If one company monopolized the purchase of the notes would that be public information? Thanks.
Thank you for weighing in. I believe interest in the company has certainly been enhanced by our recent stellar earnings report. There has also been recent media focus on risks of generic drugs produced overseas. All good for ANIP.
https://www.cbsnews.com/news/generic-drugs-manufactured-overseas-may-not-be-as-safe-as-you-think/
Maybe he's buying TEVA, lol. At least he still has plenty of shares left!
We are advertising a lot of jobs.
http://www.anipharmaceuticals.com/careers_positions.php
Isn't a "downgrade" to outperform kind of ridiculous anyway? Don't we all hope to buy stocks that outperform?
Sounds fishy to me.
Thanks BB. Meant to include you too!
Jeff, JTFM, Catty, Do you ever stop and think about how LUCKY we are? Thank you again Art Przybyl and Stephen Simes!
Hi JTFM, Makes sense. ANI is at a new level with sales, products, services through ANI-Canada, etc. A stepped-up pps is a reasonable response. Near term catalysts too!
Haven't had time to listen yet. Waiting for the transcript.
Hi BB, With all the money to be made shorting stocks in this crazy political environment, why would you pick ANIP?
Thank you Mr. Przybyl and staff for this great report. Knocked it out of the park! Looking forward to the conference call.
Break on through...watc
Wow! Thanks Yodle!
Thanks JTFM.
Catty, We cannot complain about growth!
You're not alone. No one is absolutely sure how to proceed. Analysts are very positive though.
Thanks. Meanwhile, liking 71 and change!
Don't quit your day job.
It's just a distribution agreement. Maybe it is Xyosted.
Thanks Silvr! A little weary of mystery. Announce already. I believe vancomycin would be a specialty product because of the viscosity. Antares has a patent for an injector for that type of substance. They did not have any news yesterday however.
Thanks dasgrunt. Getting interesting! Possibly vancomycin? Any thoughts?
Thanks dasgrunt. Getting interesting! Possibly vancomycin (vancomycin)?
Thanks JTFM. We do seem repositioned for growth. Hoping for a real breakout! We are due!
If not today, soon.
Launch of generic ritalin is coming up this week.
This, from the presentation is very intriguing:
Undisclosed product – via development partner
? $45M market
? Priority Review with GDUFA date of April 2019
Exciting!
I apologize if I sound like a nut but I believe this to be true: Men dominate healthcare and medical priorities in our culture. The medical community's failure to address the needs of postmenopausal women is simply an indicator of a greater cultural invisibility.
Share price up on decent volume, today of all days!
Launch coming. Maybe more news. What's up with Art selling the other day?
True enough. A good quarter anyhow. I am not promoting ATRS, Just answering the Q that was asked about why volume was up. I do, however, think an agreement for injectables with ANIP is very possible!
Bummer about Scott Gottlieb. Very good commissioner.
In regard to ATRS: drug approvals followed by good earnings report,announcement of new board member, and very positive analyst expectations.
Thank you both. Interesting posts.J
In the conference call, Art mentioned injectables (again). How can that NOT be a hint about at least a collaboration with ATRS? Especially now that contracted drug growth is soaring after the Wellspring move. Wouldn't it make sense?
More job openings in Baudette. Sounds like growth.
http://www.anipharmaceuticals.com/careers_positions.php
Thanks.
Thanks RG. FWIW, the date referenced, December 11, 2011 is in line with the Libigel bad news: 12/14/11.
The merger was later: April 12, 2013.
Wonder what's in the CT order.
https://seekingalpha.com/article/313979-with-libigel-a-failure-where-will-biosante-bottom-out
https://www.marketwatch.com/press-release/10-q-biosante-pharmaceuticals-inc-2013-05-10
Same here.
Hi JTFM, It's possible that the shutdown affected our launch. We will learn more soon. Institutional holdings are up and that's always good. We are hiring in Baudette like crazy even though Art made it sound like Toronto was the place to be. Hopefully, the costs from the Wellspring acquisition are mostly behind us. Best to you and all ANIP board contributors!
Ahem.60.
Thanks Sandrinomazzulatore